Publication:
Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke.

dc.contributor.authorEstella, Ángel
dc.contributor.authorPérez Ruiz, Miriam
dc.contributor.authorSerrano, Juan José
dc.date.accessioned2023-05-03T14:12:15Z
dc.date.available2023-05-03T14:12:15Z
dc.date.issued2022-09-17
dc.description.abstractNot all hospitals have interventional radiology services. This fact implies that in centers where this resource is not available, the treatment of stroke in the acute phase must be adapted and individualized. The aim of the study is to determine and compare the combined effect of thrombolysis and thrombectomy effectiveness and safety of tenecteplase versus alteplase in the acute treatment of ischemic stroke in patients who are candidates for endovascular therapy according to clinical practice guidelines. This paper details a retrospective multicenter cohort study of patients with ischemic stroke admitted in three hospitals between 2018 and 2020. The main outcome variables were the degree of recanalization and the functional outcome at 3 months; safety variables were mortality and the occurrence of intracranial hemorrhage (ICH). In total, 100 patients were included, 20 of which were treated with tenecteplase (TNK) and 80 with alteplase (rtPA). Of those treated with TNK, 75% obtained a successful recanalization compared to 83.8% in those treated with rtPA (OR 0.58; 95% CI 0.18-1.88; p = 0.56). No differences were found in obtaining an excellent functional result at 3 months (35% TNK vs. 58.8% rtPA; p = 0.38). Tenecteplase showed worse neurological results after 24 h (unfavorable result of 70% with TNK vs. 45% with rtPA; OR = 5.4; 95% CI 1.57-18.6). No significant differences were identified in mortality; 17.5% with rtPA and 20% with TNK (p = 0.79), nor in the appearance of intracranial hemorrhage ICH (15.2% with rtPA vs. 30% with TNK (p = 0.12). In our series, there were not significant differences shown regarding effectiveness and safety between tenecteplase and alteplase.
dc.identifier.doi10.3390/jpm12091525
dc.identifier.issn2075-4426
dc.identifier.pmcPMC9503588
dc.identifier.pmid36143310
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503588/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2075-4426/12/9/1525/pdf?version=1663749678
dc.identifier.urihttp://hdl.handle.net/10668/21387
dc.issue.number9
dc.journal.titleJournal of personalized medicine
dc.journal.titleabbreviationJ Pers Med
dc.language.isoen
dc.organizationHospital Universitario de Puerto Real
dc.organizationÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
dc.organizationAGS - Jerez, Costa Noroeste y Sierra de Cáidz
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectalteplase
dc.subjectstroke
dc.subjecttenecteplase
dc.subjectthrombolytic therapy
dc.titleEffectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9503588.pdf
Size:
275.08 KB
Format:
Adobe Portable Document Format